Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. The encoded protein also functions as an antiviral factor. [provided by RefSeq].
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot of immunoprecipitates from HEK 293 cells transfected with 1. Mock, 2.IFNAR1 WT, and 3. IFNAR1 S535A and S539A mutants showing specific immunolabeling of the ~110k to ~130k IFNAR1 WT. The immunolabeling is absent in IFNAR1 Ser535 and Ser539 mutants (Control). The immunolabeling is blocked by the phosphopeptide (Phos) used as the antigen but not by the corresponding dephosphopeptide (Dephos).
Western blot of immunoprecipitates from HEK 293 cells transfected with 1. Mock, 2.IFNAR1 WT, and 3. IFNAR1 S535A and S539A mutants showing specific immunolabeling of the ~110k to ~130k IFNAR1 WT. The immunolabeling is absent in IFNAR1 Ser535 and Ser539 mutants (Control). The immunolabeling is blocked by the phosphopeptide (Phos) used as the antigen but not by the corresponding dephosphopeptide (Dephos).
Researchers who bought this antibody have also purchased:
